LU91323I2 - Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard - Google Patents

Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard

Info

Publication number
LU91323I2
LU91323I2 LU91323C LU91323C LU91323I2 LU 91323 I2 LU91323 I2 LU 91323I2 LU 91323 C LU91323 C LU 91323C LU 91323 C LU91323 C LU 91323C LU 91323 I2 LU91323 I2 LU 91323I2
Authority
LU
Luxembourg
Prior art keywords
recombinant
human papillomavirus
ätypes
silgard
adsorbed
Prior art date
Application number
LU91323C
Other languages
English (en)
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25476357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91323(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of LU91323I2 publication Critical patent/LU91323I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/795—Composed of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91323C 1992-09-03 2007-03-08 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard LU91323I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94137192A 1992-09-03 1992-09-03
US08/032,869 US5437951A (en) 1992-09-03 1993-03-16 Self-assembling recombinant papillomavirus capsid proteins
PCT/US1993/008342 WO1994005792A1 (fr) 1992-09-03 1993-09-03 Proteines de capsides de virus du papillome recombinees a auto-assemblage

Publications (1)

Publication Number Publication Date
LU91323I2 true LU91323I2 (fr) 2007-05-08

Family

ID=25476357

Family Applications (3)

Application Number Title Priority Date Filing Date
LU91323C LU91323I2 (fr) 1992-09-03 2007-03-08 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
LU91324C LU91324I2 (fr) 1992-09-03 2007-03-08 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
LU91388C LU91388I2 (en) 1992-09-03 2007-12-14 Papillomavirus (humain types 16,18).

Family Applications After (2)

Application Number Title Priority Date Filing Date
LU91324C LU91324I2 (fr) 1992-09-03 2007-03-08 Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
LU91388C LU91388I2 (en) 1992-09-03 2007-12-14 Papillomavirus (humain types 16,18).

Country Status (13)

Country Link
US (10) US5437951A (fr)
EP (3) EP0662132B1 (fr)
JP (4) JP4046758B2 (fr)
AT (1) ATE302795T1 (fr)
AU (1) AU2004203609B2 (fr)
CA (1) CA2143845C (fr)
DE (5) DE122007000027I1 (fr)
DK (1) DK0662132T3 (fr)
ES (1) ES2248791T3 (fr)
FR (2) FR07C0020I2 (fr)
LU (3) LU91323I2 (fr)
NL (4) NL300276I1 (fr)
WO (1) WO1994005792A1 (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876922A (en) 1985-07-31 1999-03-02 Institute Pasteur Papillomavirus probe and a process for in vitro diagnosis of papillomavirus infections
ES2194839T3 (es) 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US20020164350A1 (en) * 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
ATE328068T1 (de) * 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AU683564B2 (en) * 1994-05-17 1997-11-13 University Of Queensland, The Recombinant papilloma virus L1
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US6613749B1 (en) * 1994-07-26 2003-09-02 Imperial College Innovations Limited Papovavirus pseudocapsids and use thereof for exogenous material transfer
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
DE122007000092I1 (de) * 1994-10-07 2008-03-27 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
DE19526386C1 (de) 1995-07-19 1997-01-02 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
US5725481A (en) 1996-05-17 1998-03-10 A. Fem Medical Corporation Method and apparatus for collecting vaginal fluid and exfoliated vaginal cells for diagnostic purposes
JP2000515741A (ja) * 1996-07-17 2000-11-28 アメリカ合衆国 感染性パピローマウイルス偽ウイルス粒子
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP0948351B1 (fr) * 1996-12-09 2004-02-25 Merck & Co., Inc. Particules synthetiques de nature virale de type hpv16
US6165471A (en) * 1997-07-03 2000-12-26 University Of Colorado, University Technology Corporation Homogeneous human papillomavirus capsomere containing compositions, methods for manufacture, and use thereof as diagnostic, prophylactic or therapeutic agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6991795B1 (en) 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
EP1105157B1 (fr) * 1998-08-14 2006-11-02 Merck & Co., Inc. Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus
US6284532B1 (en) * 1998-08-17 2001-09-04 Indiana University Purified human papillomavirus
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
AU762114B2 (en) * 1998-12-11 2003-06-19 University Of Queensland, The Treatment of papillomavirus infections
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
WO2000035479A1 (fr) * 1998-12-17 2000-06-22 Merck & Co., Inc. Particules viroides synthetiques a epitopes heterologues
US6689366B1 (en) * 1998-12-17 2004-02-10 Merck & Co., Inc. Synthetic virus like particles with heterologous epitopes
DE19905883C2 (de) * 1999-02-11 2001-05-23 Deutsches Krebsforsch Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AU2002367977B2 (en) 2001-08-13 2008-06-19 University Of Rochester Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
RU2225614C2 (ru) * 2002-01-11 2004-03-10 Научно-исследовательский институт детских инфекций Способ выявления антигена вируса папилломы человека
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1656561A2 (fr) * 2003-03-25 2006-05-17 BUCHNER, Erwin Procede de diagnostic precoce de carcinomes, et necessaire pour la mise en oeuvre de ce procede
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EP1831365B1 (fr) * 2004-10-08 2013-08-07 VIRxSYS Corporation Utilisation d'un trans-epissage d'arn pour le transfert genique d'anticorps et la production polypeptidique d'anticorps
EP1819835B1 (fr) 2004-12-08 2010-08-04 Gen-Probe Incorporated Detection d'acides nucleiques de types multiples de papillomavirus humains
LT5414B (lt) * 2005-04-13 2007-04-25 Biotechnologijos Institutas Monokloninių antikūnų gavimo būdas, hibridomos, gautos šiuo būdu ir rekombinantinės chimerinės į virusus panašios dalelės su įterptais kitų baltymų fragmentais kaip imunogenai hibridomų gavimui šiuo būdu
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
GB0612825D0 (en) * 2006-06-28 2006-08-09 Iti Scotland Ltd Analyte detection
GB0616508D0 (en) * 2006-08-18 2006-09-27 Iti Scotland Ltd Analyte manipulation and detection
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
PL2137210T3 (pl) 2007-03-02 2017-06-30 Glaxosmithkline Biologicals Sa Nowy sposób i kompozycje
AU2008241413A1 (en) * 2007-04-18 2008-10-30 The Regents Of The University Of California Protein-modified nano-droplets, compositions and methods of production
AU2008293575A1 (en) * 2007-08-27 2009-03-05 The Regents Of The University Of Colorado Improved methods for protein production
US9623098B2 (en) * 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
EP2414512A1 (fr) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
CA2764374C (fr) 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle
CN104288763B (zh) * 2009-06-19 2018-03-06 艾金株式会社 宫颈癌疫苗
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
CA2793214A1 (fr) * 2010-03-24 2011-09-29 University Of Rochester Formulation a base de pseudoparticules ou de capsomeres de papillomavirus et son utilisation en tant que microbicide
EP2556377B1 (fr) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
JP6153866B2 (ja) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． 迅速なハイブリッド捕捉アッセイ、及び関連する戦略的に切断されたプローブ
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
RU2610174C2 (ru) 2011-06-24 2017-02-08 Мерк Шарп И Доум Корп. Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения
US20130116408A1 (en) * 2011-11-05 2013-05-09 Aura Biosciences, Inc. Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy
WO2013119877A1 (fr) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Nanosphères dérivées de virions pour l'administration sélective d'agents thérapeutiques et diagnostiques dans des cellules cancéreuses
ES2729967T3 (es) 2012-02-07 2019-11-07 Infectious Disease Res Inst Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
WO2013139744A1 (fr) 2012-03-18 2013-09-26 Glaxosmithkline Biologicals S.A. Procédé de vaccination contre le papillomavirus humain
HRP20181102T1 (hr) 2012-05-16 2018-09-07 Immune Design Corp Cjepiva za hsv-2
MX370573B (es) 2013-04-18 2019-12-17 Immune Design Corp Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3046583B1 (fr) 2013-09-18 2019-02-13 Aura Biosciences, Inc. Conjugués de pseudo-particules virales destinés au traitement de tumeurs
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
JP2018532801A (ja) 2015-10-30 2018-11-08 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 標的化がん療法
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
WO2017200957A1 (fr) 2016-05-16 2017-11-23 Infectious Disease Research Institute Liposomes pégylés et procédés d'utilisation
MX2018014086A (es) 2016-05-16 2019-09-18 Infectious Disease Res Inst Formulacion que contiene agonista tlr y metodos de uso.
KR20250008135A (ko) 2016-06-01 2025-01-14 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2019051149A1 (fr) 2017-09-08 2019-03-14 Infectious Disease Research Institute Formulations liposomales comprenant de la saponine et procédés d'utilisation
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
CN110699328B (zh) * 2019-08-21 2022-07-19 山东省滨州畜牧兽医研究院 一种b型猪肠道病毒及其应用
JP2023516904A (ja) 2020-02-14 2023-04-21 メルク・シャープ・アンド・ドーム・エルエルシー Ｈｐｖワクチン
WO2022051022A1 (fr) 2020-09-04 2022-03-10 Infectious Disease Research Institute Arn co-lyophilisé et support lipidique nanostructuré
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
AR126708A1 (es) 2021-08-06 2023-11-08 Merck Sharp & Dohme Llc Vacuna para el vph
JP2024532127A (ja) 2021-08-19 2024-09-05 メルク・シャープ・アンド・ドーム・エルエルシー 熱安定性脂質ナノ粒子およびその使用方法
CA3266697A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine
TW202513091A (zh) 2023-06-09 2025-04-01 美商默沙東有限責任公司 用於人類乳突病毒疫苗之奈米乳液佐劑組合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106626A (en) 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
FR2524487B1 (fr) * 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4748109A (en) * 1983-07-01 1988-05-31 Baird Phillip J Assay method and reagent to determine antibodies to papillomavirus virions
EP0133123A1 (fr) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Immunogènes de papillomavirus
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
JP2648303B2 (ja) * 1985-04-04 1997-08-27 ジョージタウン・ユニバーシティ 型特異的乳頭腫ウイルスｄｎａ配列およびペプチド
US5081029A (en) * 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
DE3625257A1 (de) 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
US5071757A (en) * 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5186933A (en) * 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
FR2629458B2 (fr) * 1987-07-31 1991-08-09 Ire Celltarg Sa Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5039607A (en) * 1988-05-17 1991-08-13 Syntex (U.S.A.) Inc. Method for immunochromatographic analysis
US5045447A (en) * 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NZ232913A (en) 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
NL8902301A (nl) 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
EP0451550A3 (en) 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
FR2661921B1 (fr) * 1990-05-11 1992-08-07 Pasteur Institut Sonde a papillomavirus (hpv66), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
ES2194839T3 (es) * 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
EP1835029A1 (fr) * 1992-06-25 2007-09-19 Georgetown University Vaccins de papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
ATE492289T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
US5874089A (en) 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
US5758284A (en) * 1995-11-30 1998-05-26 Lucent Technologies Inc. Increasing the capacity of a personal communication service system by utilization of the bridged shared line appearance feature
CA2295316C (fr) 1997-07-03 2007-06-26 University Of Colorado, University Technology Corporation Compositions renfermant des capsomeres de papillomavirus humain homogene, leurs procedes de production et leurs procedes d'utilisation en tant qu'agents diagnostiques, prophylactiques ou therapeutiques
DE69929232T2 (de) 1998-10-21 2006-08-31 The United States Government As Represented By The Department Of Health And Human Services Virusähnliche partikel zur induktion von autoantikörpern
EP1271151A1 (fr) 2001-06-20 2003-01-02 Virofem Diagnostika GmbH Système de test et procédé de détection des anticorps de virus du papillome humain (HPV)

Also Published As

Publication number Publication date
CA2143845A1 (fr) 1994-03-17
NL300275I1 (nl) 2007-05-01
US20030050439A1 (en) 2003-03-13
LU91388I2 (en) 2008-02-14
JPH08504087A (ja) 1996-05-07
US7220419B2 (en) 2007-05-22
EP1538209A2 (fr) 2005-06-08
NL300325I1 (nl) 2008-03-03
EP1621635A2 (fr) 2006-02-01
FR07C0020I1 (fr) 2007-04-27
AU2004203609A1 (en) 2004-09-02
US5985610A (en) 1999-11-16
US7361356B2 (en) 2008-04-22
DE69333859T2 (de) 2006-06-08
FR08C0003I1 (fr) 2008-03-21
US5871998A (en) 1999-02-16
EP0662132B1 (fr) 2005-08-24
DE122007000029I1 (de) 2007-07-12
LU91324I2 (fr) 2007-05-08
ATE302795T1 (de) 2005-09-15
AU4847593A (en) 1994-03-29
ES2248791T3 (es) 2006-03-16
JP2001333788A (ja) 2001-12-04
US20030219873A1 (en) 2003-11-27
FR07C0020I2 (fr) 2012-08-03
DE69333859D1 (de) 2005-09-29
CA2143845C (fr) 2003-11-18
AU2004203609B2 (en) 2009-10-01
US5709996A (en) 1998-01-20
JP4046758B2 (ja) 2008-02-13
DE122007000028I1 (de) 2007-07-12
NL300274I1 (nl) 2007-05-01
NL300276I1 (nl) 2007-05-01
JP2004194672A (ja) 2004-07-15
EP0662132A1 (fr) 1995-07-12
JP2004208696A (ja) 2004-07-29
US5756284A (en) 1998-05-26
US5744142A (en) 1998-04-28
DE122008000010I1 (de) 2008-06-05
AU683220B2 (en) 1997-11-06
DK0662132T3 (da) 2005-11-21
US5716620A (en) 1998-02-10
US5437951A (en) 1995-08-01
EP1538209A3 (fr) 2008-02-20
EP1621635A3 (fr) 2009-10-21
JP4046949B2 (ja) 2008-02-13
WO1994005792A1 (fr) 1994-03-17
US20060269954A1 (en) 2006-11-30
DE122007000027I1 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
LU91323I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé).-silgard
FR07C0073I2 (fr) Vaccin contre le papillomavirus